Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Japanese technology firm SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF) is planning to infuse around $1.2 billion via convertible debt into genetic-testing provider Invitae Corp (NYSE: NVTA), the Wall Street Journal reports.
- The convertible debt investment will help Invitae to expand its platform utility. The notes have an initial conversion price of $43.18 per share, signifying a 20% premium to the company’s trailing 5-day average as of April 1.
- Invitae’s shares have tripled in a year. The stock closed at $39.19 last Thursday, hitting a market valuation of $7.7 billion.
- SoftBank’s investments are aimed at biotech and life-science portfolio expansion. It has recently invested in multiple U.S. life-sciences company initial public offerings (IPOs). SoftBank’s public holdings included Pacific Biosciences Of California Inc (NASDAQ: PACB), 4D Molecular Therapeutics Inc (NASDAQ: FDMT), and AbCellera Biologics Inc (NASDAQ: ABCL).
- Price action: NVTA shares traded higher by 9.9% at $42 in the premarket session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!